The financial asphyxiation is tightening in Spanish public administrations concerned to Big Pharmaceuticals, and spending on outpatient pharmacy cannot be reduced further. Thinks so, at least Farmaindustria, the management of laboratories, this Friday rebuked the Executive, who never tires of asking for more measures to hold spending, which continues to saving in this chapter will be very difficult. ‘We can do more efforts. It has touched ground in pharmaceutical expenditures,’ noted the CEO, Humberto harness.
With forecasts that handle the employers, it’s time to put focus on other items of expenditure or investment in public health. ‘Pharmaceutical spending is under control as the new reference price system prevents out of control expenditure’. Therefore, ask the Government to provide ‘stability to the tranquility in this situation and show a transparent, realistic and balanced approach’. In addition, ensure that ‘no room’ for the NHS is sustainable. ‘They go through actions in areas such as preventive medicine, hospital infrastructure and standardization of treatment.’
The CEO also stressed on the ‘need’ to be greater access to innovations with prices competitive and respectful to the principles of industrial property and at the same time, these prices are also ‘aligned’ with the standards of the countries with which Spain competes.
The accumulated debt is one of the endemic problems of the sector. The network of public hospitals has bills in the drawers held with the pharmaceutical industry reached 4,290 million euros. The employers are confident that the new providers tranche of the Government of Mariano Rajoy yesterday approved in the Council of Ministers will enable the sector to recover, at least 2,600 million of total debt.
At a meeting of the management, direction has remained with a group of journalists in Cuenca, managers were hopeful that pharmaceutical companies will benefit from the new section of the plan providers, once the Executive did not include them in the first. The late payment of medical bills reached an average of 343 days. ‘It is essential to have a favorable climate for the industry and that the country is serious about paying their debts,’ said Javier Urzay, Farmaindustria deputy, who has defended the system of centralized purchasing of drugs launched by the Ministry of Health, but has requested that there be no ‘second round’ in the regions.
The technical department director Farmaindustria, Emili Esteve, believes the draft of Royal Decree of Ministry of Health for regulating the reference price system and homogeneous groups of drugs in NHS ‘can be improved’. Also, Esteve has highlighted the need for drug sets are ‘sufficiently homogeneous’ to avoid having to stop falling prices without drugs to market. ‘The possibility of creating subsets and these subsets put a price to them is something that, in principle, the Board of State suggested that it could be done in a Royal Decree. This is important when the difference in very high doses, as with the drugs to the respiratory system,’ he added.
It must be the system itself to provide the information, not the suppliers. The president of the employers, Elvira Sanz recalled that this sector is ‘largoplacista’ and also to collaborate with different ministries, councils and scientific societies to ensure sustainability of the NHS, provides ‘much value’ to the industrial and research. ‘We do everything we know and everything we can,’ he said at the opening of the conference.
For more about health: http://www.reviewlity.com/